Cytochrome P450 4A11/22 Antibody | Affinity Biosciences

IF/ICC
Cites

1/2

Figure 2 Effects of FFA, clofibrate and HET0016 on Oil Red staining, TG and CYP4A11 synthesis in HepG2 cells.

Product:	Cytochrome P450 4A11/22 Antibody
Catalog:	DF4749
Description:	Rabbit polyclonal antibody to Cytochrome P450 4A11/22
Application:	WB IF/ICC
Reactivity:	Human
Prediction:	Bovine, Dog
Mol.Wt.:	60 KD; 59kD(Calculated).
Uniprot:	Q02928 \| Q5TCH4
RRID:	AB_2837103

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MS Report

HPLC Report

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:1000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human

Prediction:

Bovine(82%), Dog(82%)

Clonality:

Polyclonal

Specificity:

Cytochrome P450 4A11/22 Antibody detects endogenous levels of total Cytochrome P450 4A11/22.

RRID:

AB_2837103
Cite Format: Affinity Biosciences Cat# DF4749, RRID:AB_2837103.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

20-HETE synthase; 20-hydroxyeicosatetraenoic acid synthase; CP4AB_HUMAN; CYP4A; Cyp4a1; Cyp4a10; CYP4A11; Cyp4a14; Cyp4a3; CYP4A7; CYP4AII; CYPIVA11; Cytochrome P-450HK-omega; Cytochrome P450 4A1; Cytochrome P450 4A10; Cytochrome P450 4A11; Cytochrome P450 4A14; Cytochrome P450 4A2; Cytochrome P450 4A3; Cytochrome P450 4A7; Cytochrome P450HL-omega; Fatty acid omega-hydroxylase; Lauric acid omega-hydroxylase;

Immunogens

Immunogen:

Uniprot:

Q02928(CP4AB_HUMAN) >>Visit HPA database.

Q5TCH4(CP4AM_HUMAN) >>Visit HPA database.

Gene(ID):

CYP4A11(1579) | CYP4A22(284541)

Expression:

Q02928 CP4AB_HUMAN:

Expressed in liver (PubMed:7679927). Expressed in S2 and S3 segments of proximal tubules in cortex and outer medulla of kidney (PubMed:7679927, PubMed:10660572).

Sequence:

Q02928 CP4AB_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLFGHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSYRFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQDSPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQNDTIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKMENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGASITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHHNPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFELLPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL

Q5TCH4 CP4AM_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MSVSVLSPSRRLGGVSGILQVTSLLILLLLLIKAAQLYLHRQWLLKALQQFPCPPSHWLFGHIQEFQHDQELQRIQERVKTFPSACPYWIWGGKVRVQLYDPDYMKVILGRSDPKSHGSYKFLAPRIGYGLLLLNGQTWFQHRRMLTPAFHNDILKPYVGLMADSVRVMLDKWEELLGQDSPLEVFQHVSLMTLDTIMKSAFSHQGSIQVDRNSQSYIQAISDLNSLVFCCMRNAFHENDTIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKMENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHGLLGDGASITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHHNPKVWPNLEVFDPSRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNQLKVARALTLLRFELLPDPTRIPIPMARLVLKSKNGIHLRLRRLPNPCEDKDQL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Bovine

Dog

Pig

Horse

Sheep

Xenopus

Zebrafish

Chicken

Rabbit

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q02928/Q5TCH4 As Substrate

Q02928
Q5TCH4

Site	PTM Type	Source
S7	Phosphorylation	Uniprot
S307	Phosphorylation	Uniprot
S394	Phosphorylation	Uniprot
T395	Phosphorylation	Uniprot
T485	Phosphorylation	Uniprot

Site	PTM Type	Source
S2	Phosphorylation	Uniprot
S4	Phosphorylation	Uniprot
S7	Phosphorylation	Uniprot
S9	Phosphorylation	Uniprot
Y88	Phosphorylation	Uniprot
Y100	Phosphorylation	Uniprot
Y104	Phosphorylation	Uniprot
K106	Acetylation	Uniprot
K115	Acetylation	Uniprot
S307	Phosphorylation	Uniprot
S394	Phosphorylation	Uniprot
T395	Phosphorylation	Uniprot

Research Backgrounds

Q02928_CP4AB_HUMAN
Q5TCH4_CP4AM_HUMAN

Function:

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids and their oxygenated derivatives (oxylipins). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of saturated and unsaturated fatty acids, the catalytic efficiency decreasing in the following order: dodecanoic > tetradecanoic > (9Z)-octadecenoic > (9Z,12Z)-octadecadienoic > hexadecanoic acid. Acts as a major omega-hydroxylase for dodecanoic (lauric) acid in liver. Participates in omega-hydroxylation of (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure. Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of fatty acids with lower efficiency. May contribute to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening. Omega-hydroxylates (9R,10S)-epoxy-octadecanoate stereoisomer. Plays a minor role in omega-oxidation of long-chain 3-hydroxy fatty acids. Has little activity toward prostaglandins A1 and E1.

Subcellular Location:

Endoplasmic reticulum membrane>Peripheral membrane protein. Microsome membrane>Peripheral membrane protein.

Tissue Specificity:

Expressed in liver. Expressed in S2 and S3 segments of proximal tubules in cortex and outer medulla of kidney.

Family&Domains:

Belongs to the cytochrome P450 family.

Function:

Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. Shows no activity towards arachidonic acid and prostaglandin A1. Lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis.

Subcellular Location:

Endoplasmic reticulum membrane>Peripheral membrane protein. Microsome membrane>Peripheral membrane protein.

Family&Domains:

Belongs to the cytochrome P450 family.

Research Fields

· Metabolism > Lipid metabolism > Fatty acid degradation.

· Metabolism > Lipid metabolism > Arachidonic acid metabolism.

· Metabolism > Metabolism of cofactors and vitamins > Retinol metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction. (View pathway)

References

1). CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROS‑induced lipid peroxidation and inflammation. International Journal of Molecular Medicine (PubMed: 32124935) [IF=5.4]

Application: WB Species: Human Sample: HepG2 cells

Figure 2 Effects of FFA, clofibrate and HET0016 on Oil Red staining, TG and CYP4A11 synthesis in HepG2 cells. HepG2 cells were treated with FFA (1 mM), FFA + clofibrate (100 µM) or FFA + HET0016 (1 µM) solution for 24 h. (A) Lipid droplets in HepG2 cells were stained with Oil Red O. Scale bar, 200 µm. (B) The effects of these treatments on TG content in HepG2 cells was measured. (C) ALT and AST level in FFA-induced HepG2 cells. (D) The mRNA level of CYP4A11 was examined by reverse transcription-quantitative polymerase chain reaction. (E) The protein level of CYP4A11 was assessed by western blot analysis. The results are presented as the mean ± standard deviation. *P

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

Cytochrome P450 4A11/22 Antibody - #DF4749